| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.01 |
| mRNA | ABT-263 | FIMM | pan-cancer | AAC | -0.36 | 0.01 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.02 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.077 | 0.02 |